Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.

Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.

UNLABELLED: Two mitogen-activated protein kinase kinase (MAPK2, also known as MEK) inhibitors were assessed with (18)F-FDG PET in separate phase I clinical studies, clearly illustrating the potential of metabolic imaging for dose, dosing regimen, and compound selection in early-phase trials and uti...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Kraeber-Bodéré, F, Carlier, T, Naegelen, V, Shochat, E, Lumbroso, J, Trampal, C, Nagarajah, J, Chua, S, Hugonnet, F, Stokkel, M, Gleeson, F, Tessier, J
Natura:	Journal article
Lingua:	English
Pubblicazione:	2012

Documenti analoghi

Interest of FDG-PET in the Management of Mantle Cell Lymphoma
di: Clément Bailly, et al.
Pubblicazione: (2019-04-01)

QUANTITATIVE EVALUATION OF THERAPEUTIC RESPONSE BY FDG PET-CT IN METASTATIC BREAST CANCER
di: Dorothée eGOULON, et al.
Pubblicazione: (2016-05-01)

Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
di: Leijen, S, et al.
Pubblicazione: (2012)

18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin’s disease
di: Catherine Ansquer, et al.
Pubblicazione: (2008-01-01)

Prognostic value and clinical impact of 18FDG-PET in the management of children with Burkitt lymphoma after induction chemotherapy.
di: clement eBailly, et al.
Pubblicazione: (2014-12-01)

The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma.
di: Chowdhury, F, et al.
Pubblicazione: (2008)

18F-FDG PET/CT of cervical carcinoma.
di: Patel, C, et al.
Pubblicazione: (2011)

DCE-MRI to distinguish all monoclonal plasma cell disease stages and correlation with diffusion-weighted MRI/PET-based biomarkers in a hybrid simultaneous whole body-2-[18F]FDG-PET/MRI imaging approach
di: Bastien Jamet, et al.
Pubblicazione: (2024-07-01)

Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma.
di: Clement Bailly, et al.
Pubblicazione: (2017-01-01)

Assessment of lymph nodes and prostate status using early dynamic curves with 18F-choline PET/CT in prostate cancer
di: Cédric eMathieu, et al.
Pubblicazione: (2015-09-01)

18FDG PET in lymphoma
di: Goldsmith Stanley J.
Pubblicazione: (2012-01-01)

Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma
di: Caroline Bodet-Milin, et al.
Pubblicazione: (2008-03-01)

CLINICAL AND SURVIVAL IMPACT OF FDG PET IN PATIENTS WITH SUSPICION OF RECURRENT OVARIAN CANCER: A 6-YEAR FOLLOW-UP
di: Daniela eRusu, et al.
Pubblicazione: (2015-07-01)

Interest of Pet Imaging in Multiple Myeloma
di: Bastien Jamet, et al.
Pubblicazione: (2019-04-01)

Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial
di: Caroline Bodet-Milin, et al.
Pubblicazione: (2023-10-01)

Specific features to differentiate Giant cell arteritis aortitis from aortic atheroma using FDG-PET/CT
di: Olivier Espitia, et al.
Pubblicazione: (2021-08-01)

Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: prevalence and disease pattern.
di: Chowdhury, F, et al.
Pubblicazione: (2009)

Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project
di: Clément Bailly, et al.
Pubblicazione: (2020-01-01)

Myocarditis on 18FDG-PET imaging
di: Nourhan Chaaban, MD, et al.
Pubblicazione: (2022-06-01)

Applications of 18(F) FDG PET/CT in oncology
di: Ahmad Saad, Fathinul Fikri, et al.
Pubblicazione: (2015)

Re: Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: prevalence and disease pattern-a reply
di: Chowdhury, F, et al.
Pubblicazione: (2010)

Revisiting the Robustness of PET-Based Textural Features in the Context of Multi-Centric Trials.
di: Clément Bailly, et al.
Pubblicazione: (2016-01-01)

The 18F-FDG PET scan in oncology
di: T Thientunyakit
Pubblicazione: (2007-12-01)

A guideline proposal for mice preparation and care in 18F-FDG PET imaging
di: F. M. Ribeiro, et al.
Pubblicazione: (2022-08-01)

18F-FDG PET/MRI and 18F-FDG PET/CT for the Management of Gynecological Malignancies: A Comprehensive Review of the Literature
di: Leila Allahqoli, et al.
Pubblicazione: (2023-10-01)

Incidental findings on 18-FDG PET–CT in head and neck cancer. A retrospective case-control study of incidental findings on 18-FDG PET–CT in patients with head and neck cancer
di: Casselden, E, et al.
Pubblicazione: (2018)

18FDG-PET and large vessel vasculitis: preliminary data on 25 patients
di: L. Feggi, et al.
Pubblicazione: (2011-09-01)

2-deoxy-2-[18]fluoro-D-glucose PET/CT (18FDG PET/CT) may not be a viable biomarker in Pompe disease
di: U. Plöckinger, et al.
Pubblicazione: (2018-03-01)

Scar sarcoidosis on 18F-FDG PET/CT
di: Saurabh Arora, et al.
Pubblicazione: (2019-06-01)

Osteomyelitis detected by 18F-FDG PET-CT
di: Alberto Martinez-Lorca, et al.
Pubblicazione: (2024-05-01)

Semiquantitative 2-[18F]FDG PET/CT-based parameters role in lymphoma
di: Domenico Albano, et al.
Pubblicazione: (2024-12-01)

Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence
di: Piva R, et al.
Pubblicazione: (2017-07-01)

Total metabolic tumor volume on 18F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy
di: Nicolas Martin, et al.
Pubblicazione: (2024-04-01)

FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma
di: Pierre-Yves Salaun, et al.
Pubblicazione: (2008-08-01)

Properties of S. aureus spondylodiscitis in CT and F18-FDG-PET/CT
di: J. Hockmann, et al.
Pubblicazione: (2024-01-01)

The Use of 18F-FDG-PET/CT for Diagnosis and Treatment Monitoring of Inflammatory and Infectious Diseases
di: Andor W. J. M. Glaudemans, et al.
Pubblicazione: (2013-01-01)

Is integrated 18F-FDG PET/MRI superior to 18F-FDG PET/CT in the differentiation of incidental tracer uptake in the head and neck area?
di: Benedikt Michael Schaarschmidt, et al.
Pubblicazione: (2017-03-01)

Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma
di: Vijay Mistry, et al.
Pubblicazione: (2023-01-01)

Metástasis musculares no sospechadas detectadas con 18F-FDG PET/TC
di: J. San Román, et al.
Pubblicazione: (2017-01-01)

The systemic impact of different COVID-19 vaccines in 2-[18F] FDG-PET/CT
di: Tina Nazerani-Zemann, et al.
Pubblicazione: (2023-12-01)